What is the mechanism of action (Moa) of Rifampicin (rifampin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Rifampicin inhibits bacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, preventing transcription initiation, as stated in the American Journal of Respiratory and Critical Care Medicine 1. This mechanism of action allows rifampicin to be bactericidal against actively growing mycobacteria and many gram-positive and gram-negative bacteria. The drug specifically targets bacterial RNA polymerase while having minimal effect on human RNA polymerase, giving it selective toxicity. Some key points about rifampicin include:

  • It penetrates well into tissues and cells, including macrophages, which makes it particularly effective against intracellular pathogens like Mycobacterium tuberculosis.
  • Rifampicin is typically used at doses of 600mg daily for adults in tuberculosis treatment regimens, usually in combination with other antibiotics to prevent resistance development, as recommended in the Clinical Infectious Diseases journal 1.
  • Rifampicin induces cytochrome P450 enzymes, which can significantly decrease the effectiveness of many medications including oral contraceptives, warfarin, and antiretrovirals, so drug interactions must be carefully monitored, as noted in 1.
  • Patients should be informed that rifampicin will cause orange-red discoloration of body fluids including urine, tears, and sweat, as mentioned in 1. Some important considerations for rifampicin use include:
  • Potential interactions with other medications, such as antiretrovirals, oral contraceptives, and warfarin, which may require dose adjustments or alternative treatments, as discussed in 1.
  • The need for careful monitoring of patients with HIV infection or those taking other medications that may interact with rifampicin, as recommended in 1.

From the FDA Drug Label

Mechanism of Action Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.

The mechanism of action of rifampicin is the inhibition of DNA-dependent RNA polymerase activity in susceptible organisms, specifically interacting with bacterial RNA polymerase without affecting the mammalian enzyme 2.

From the Research

Mechanism of Action of Rifampicin

  • Rifampicin is a bactericidal antibiotic that inhibits RNA polymerase (RNAP) in bacteria, thereby preventing RNA synthesis 3.
  • The inhibitor binds in a pocket of the RNAP beta subunit deep within the DNA/RNA channel, but more than 12 A away from the active site 3.
  • Rifampicin acts by directly blocking the path of the elongating RNA when the transcript becomes 2 to 3 nt in length 3.
  • This mechanism of action explains the effects of rifampicin on RNAP function and its potent antibacterial activity 3.

Use of Rifampicin in Tuberculosis Treatment

  • Rifampicin is a key component of anti-tuberculosis therapy and is often used in combination with other drugs such as isoniazid, ethambutol, and pyrazinamide 4, 5, 6.
  • The combination of rifampicin and isoniazid is effective in treating tuberculosis, including cases with isoniazid-resistant strains 4.
  • Rifampicin can be used in patients with various conditions, including pregnancy, diabetes mellitus, and renal failure, although dose adjustments may be necessary in some cases 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.